R
Renalys
renalys.com
Website unreachable since Oct 25, 2026
The startup operates a therapeutic platform that utilizes a first-in-class oral Dual Endothelin Angiotensin Receptor Antagonist (DEARA) to inhibit the progression of IgA Nephropathy (IgAN) by targeting the Endothelin-1 and Angiotensin II pathways. This approach provides Asian patients with a viable alternative to existing treatments that are often inadequate for managing renal disease.
Traction –/10
Tokyo, Japan · HQ
- Biotechnology
- Healthcare Technology
Updated 5 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup operates a therapeutic platform that utilizes a first-in-class oral Dual Endothelin Angiotensin Receptor Antagonist (DEARA) to inhibit the progression of IgA Nephropathy (IgAN) by targeting the Endothelin-1 and Angiotensin II pathways. This approach provides Asian patients with a viable alternative to existing treatments that are often inadequate for managing renal disease.